The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand’s pharmaceutical benefit package

There is increasing impetus to use pharmaceutical interventions, ie, ranibizumab or bevacizumab, for the treatment of particular macular diseases. This paper describes the evidence and decision-making of the National List of Essential Medicines Committee that recently announced the inclusion of beva...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Anothaisintawee, Thunyarat, Leelahavarong, Pattara, Ratanapakorn, Tanapat, Teerawattananon, Yot
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2012
Soggetti:
Perspectives
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3520463/
https://ncbi.nlm.nih.gov/pubmed/23248574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S37458
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi